IP Library Granted Patent US 7,515,952
Granted Patent B2
US 7,515,952 · App. 10/240,367 · Granted Apr 7, 2009

System for characterization and mapping of tissue lesions

Assignee: Forth Photonics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,515,952
App. No.
10/240,367
Granted
Apr 7, 2009
Kind
B2
Abstract

The present invention provides a method and an apparatus for the in vivo, non-invasive, early detection of alterations and mapping of the grade of these alterations, caused in the biochemical and/or in the functional characteristics of epithelial tissues during the development of tissue atypias, dysplasias, neoplasias and cancers. The method is based, at least in part, on the simultaneous measurement of the spatial, temporal and spectral alterations in the characteristics of the light that is re-emitted from the tissue under examination, as a result of a combined tissue excitation with light and special chemical agents. The topical or systematic administration of these agents result in an evanescent contrast enhancement between normal and abnormal areas of tissue. The apparatus enables the capturing of temporally successive imaging in one or more spectral bands simultaneously. Based on the measured data, the characteristic curves that express the agent-tissue interaction kinetics, as well as numerical parameters derived from these data, are determined in any spatial point of the examined area. Mapping and characterization of the lesion, are based on these parameters.

Claims (22)

1. An optical imaging system for diagnosing and mapping a tissue abnormality, the system comprising:

a. an applicator configured to apply a pathology differentiating agent on a living tissue sample under analysis, wherein said pathology differentiating agent provokes a transient alteration in an optical property of said living tissue sample;

b. a light source configured to illuminate the living tissue sample with broad band, continuous wave optical radiation;

c. one or more optical filters configured to select a spectral band of light for imaging and/or illumination;

d. an optical imaging head comprising:

i. optics for collecting and focusing light remitted by the living tissue sample under analysis; and

ii. one or more optical imaging detectors connected with a data digitizing board and a computer for capturing a plurality of images of the living tissue sample at various time instances, before and after the application of said pathology differentiating agent;

e. a probing device, wherein said device facilitates the visualization and imaging of the living tissue sample;

f. a mechanical shaft connecting said optical imaging head with said probing device, whereby a relative motion between said living tissue sample and the optical imaging head is substantially eliminated and captured images in time succession are substantially registered or aligned; and

wherein said computer comprises data storage, processing and analysis software, and hardware,

said computer programmed to perform modeling and parametric analysis of a pixel value (PV XY ) vs. time curve obtained from a pixel value (PV XY ) for a given XY spatial location in the plurality of images of said living tissue sample at various time instances, and programmed to calculate a dynamic optical property based on the curve of (PV XY ) vs. time over a time-course that encompasses both (i) a rising interval in a pixel value (PV XY ) vs. time curve obtained from a pixel value PV XY for a given XY spatial location in the plurality of images of said living tissue sample captured at the various time instances, said rising interval occurring between said application of said pathology differentiating agent and a maximum value of said pixel value (PV XY ) in said pixel value vs. time curve, and (ii) a relaxation time interval in said pixel value (PV XY ) vs. time curve, said relaxation time interval occurring after said maximum value of (PV XY ) until a substantial ending time of said transient alteration, wherein said dynamic optical property is an area under the pixel value (PV XY ) vs. time curve; and

wherein said computer is programmed to convert said dynamic optical property to a pathology index by correlating and calibrating said dynamic optical property with a diagnosis to detect a tissue abnormality in said living tissue sample;

wherein said computer is programmed to calculate said dynamic optical property at each of a plurality of spatial pixel locations and to create and display a first image, wherein said first image expresses the spatial distribution of said dynamic optical property or said image expresses a spatial distribution of said pathology index;

wherein said dynamic optical property calculated at a plurality of spatial pixel locations or a plurality of said pathology indices calculated at a plurality of spatial locations are represented using a scale of pseudocolors, thereby generating a dynamic optical property pseudocolor image or a pathology pseudocolor image.

2. The optical imaging system of claim 1 wherein said optics for collecting and focusing the remitted light are selected from the group consisting of lenses, medical microscopes, surgical microscopes, colposcopes, and endoscopes.

3. The optical imaging system of claim 1 wherein said probing device is a vaginal speculum.

4. The optical imaging system of claim 1 wherein said living tissue sample is a cervix of the uterus.

5. The optical imaging system of claim 1 further including a display which displays said first dynamic optical property pseudocolor image or said pathology pseudocolor image superimposed on (1) a previously recorded image of said living tissue sample; or (2) a real time displayed image of said living tissue sample.

6. The optical imaging system of claims claim 1 wherein said pathology differentiating agent is selected from an acidic or basic solution.

7. The optical imaging system of claim 6 wherein the acidic solution is an acetic acid solution.

8. The optical imaging system of claim 1 wherein said living tissue sample is comprised of tissue selected from the group consisting of epithelial tissue, gastrointestinal track tissue, respiratory track tissue, oral cavity tissue, oesophagus tissue, colon tissue, stomach tissue, vagina tissue, uterus tissue, and skin tissue, and said abnormality is selected from the group consisting of condylomas, atypias, dysplasias, neoplasias, Cervical Intraepithelial Neoplasias (CIN) I, II, III and cancers.

9. The optical imaging system claim 1 wherein said pathology differentiating agent alters at least one characteristic of light re-emitted from the tissue, wherein said at least one characteristic is selected from the group consisting of reflection, diffuse scattering and fluorescence.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 27, 2023
From: KREOS CAPITAL V (UK) LIMITED
To: DYSIS MEDICAL LIMITED
Reel/Frame 065959/0936 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCETO: SECURITY INTEREST PREVIOUSLY RECORDED ON REEL 041152 FRAME 0237. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Feb 6, 2017
From: DYSIS MEDICAL LIMITED
To: KREOS CAPITAL V (UK) LIMITED
Reel/Frame 041660/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: DYSIS MEDICAL LIMITED
To: KREOS CAPITAL V (UK) LIMITED
Reel/Frame 041152/0237 →
CHANGE OF NAME Recorded Dec 21, 2016
From: FORTH PHOTONICS LIMITED
To: DYSIS MEDICAL LIMITED
Reel/Frame 041187/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2005
From: BALAS, CONSTANTINOS; PELECOUDAS, DEMETRIOS; FOUNDATION OF RESEARCH AND TECHNOLOGY HELLAS, THE
To: FORTH PHOTONICS LIMITED
Reel/Frame 016656/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2003
From: BALAS, KONSTANTINOS; PELECOUDAS, DEMETROIS
To: FOUNDATION OF RESEARCH AND TECHNOLOGY, A.K.A. I.T.E
Reel/Frame 013571/0301 →
Priority Claims (1)
GR 20000-100102 · Mar 28, 2000 · national
Continuity (1)
Related Publication 20030114762A1 · Jun 19, 2003